👉University of Michigan Scleroderma Program leading the way through excellence in clinical care, teaching, & research #scleroderma tweets≠advice Follow≠endorse
Exciting data on CAR-T from @Worldsclerofnd meeting in Athens in #scleroderma. Complete B cell depletion in tissue, response in RNA pol 3 Ab, and ++large clinical response. Clinical trials starting comparing CAR-T to standard of care therapies with Novartis and BMS.
Join me and Dr Monalisa Ghosh to get an update on cell therapy in # scleroderma on Friday, December 12 - 2:00 p.m. ET. Sponosred by @scleroderma https://t.co/vnIMEVJkQU
SLS 3 is published. https://t.co/gXyyHJLkp0
1. Upfront MMF+PFD vs. MMF+PLA
2. Underpowered due to Covid
3. No difference in primary end- FVC%
4. ⬆️AE and discont with MMF+PFD
What else did we learn?
A. Trends favor MMF+PFD in PROs and in HRCT QILD
B. Need well powered trials
✨How can we better understand and treat fibrotic diseases?
Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM
He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.
📢 There were “clinical improvements in lung function and skin thickness in patients with severe refractory #SSc, with 96% remaining off SSc-directed therapies during the follow up,” said Dr. Dinesh Khanna @sclerodermaUM.
https://t.co/bhdPC5sRaf
📢 “Preliminary meaningful improvement in #lung function and #skin thickness was observed” in patients with #SSc who received #CARTcelltherapy, said Dr. Dinesh Khanna @sclerodermaUM.
Read the full story from #ACR25 here 👇
https://t.co/bhdPC5sRaf
#ACR2025. Exciting data on CAR-T in SSc.
Oct 26: Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy: Phase 1 Trial in SSc
Oct 27: RESET-SSc: Clinical Trial Evaluating Rese-cel Autologous 4-1BB CD19-CAR T Cell Therapy in Phase 1 in SSc
Interested in a career in scleroderma and related disorders? Join one of the largest programs with robust clinical research and trials. We are actively recruiting! @UMIntMed
https://t.co/lDtCfruoWr
📷
Interested in a career in scleroderma and related disorders? Join one of the largest programs with robust clinical research and trials. We are actively recruiting! @UMIntMed
https://t.co/lDtCfruoWr
📷
Interested in a position at U-M scleroderma program? Expertise in analyzing omics data. We are leading center in clinical trials and one of the largest scleroderma program.
https://t.co/hoMCUzTHcb
Join us today at 12 pm for Grand Rounds on "Systemic Sclerosis: An Update" presented by @sclerodermaUM, professor in the Division of Rheumatology.
Learn more: https://t.co/H8svS3VM1m
DID YOU KNOW? >30% of Systemic Sclerosis pts present without Raynauds!. Data from 2 large US cohorts, of SSc dx with puffy fingers/hands or other symptoms. Such patients presented with more severe skin and musculoskeletal disease. https://t.co/NP3KeUL5iX
Bringing rheumatology closer to haematology. CAR-T therapy is showing tremendous promise in autoimmune conditions esp difficult to treat cases. #eular2025